Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

3 years ago

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapyWARMINSTER, Pa. and OXFORD, United…

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

3 years ago

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…

Jushi Holdings Inc. Opens 33rd Retail Location Nationwide and Fourth Dispensary in Nevada

3 years ago

NuLeaf Las Vegas The Strip, Located by 18b Las Vegas Arts District on The Las Vegas Strip, to Begin Serving…

BridgeBio Pharma to Participate in June Investor Events

3 years ago

PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage…

Titan Medical Appoints Bill Fahey as Vice President, Manufacturing and Operations

3 years ago

TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the…

VitalHub Signs Multi-Year Licensing Agreement to Provide an Electronic Medical Record Solution for Provincial Adult Correctional Facilities across Ontario

3 years ago

TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSX: VHI) is pleased to announce that TREAT has…

Radius Files Definitive Proxy and Mails Letter to Stockholders

3 years ago

Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew…

Quipt Home Medical on Preliminary List to Join Russell Microcap® Index

3 years ago

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

3 years ago

Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and…

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

3 years ago

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared…